Enterprise Value to EBITDA Ratio: Apollomics Corp (APLM)
Apollomics, Inc. (APLM) is a biotech developer of anti-tumor agents whose unique innovations for combating lung mutations pave the way for market dominance. The market capitalization trend on GURU.Markets is 0.00, which correlates with a high concentration of assets in the US and Chinese markets. The potential success of late-stage trials and the release of webreltinib will provide the company with strong pricing power due to low demand elasticity.
Metric breakdowns and analytics for apollomicsinc.com (APLM)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
APLM - Company Net Income|Expected Profit Apollomics, Inc.|APLM - Market Cap to Earnings|Future Price to Earnings Apollomics|APLM - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Apollomics, Inc.|APLM - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Apollomics|APLM - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months apollomicsinc.com|APLM - Expected net earnings per share growth this year|Expected earnings per share growth for next year Apollomics, Inc.
Fundamental valuation:APLM (Apollomics Corp)
This ratio compares the total enterprise value, including debt, with its operating profitability, allowing for an assessment of the business's real value regardless of tax and credit burdens. By analyzing the EV/EBITDA of this capital-intensive business, an investor can see how current inhibitor sales in China offset the costs of U.S. R&D research, which determines the current level of investment attractiveness for Apollomics, Inc. (APLM).
Competitor analysis
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|EV/EBITDA Multiple delcath.com (DCTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Therapeutics, Inc. YMAB|AURA (Aura Biosciences Inc) - Company Value to Operating Income Before Depreciation Ratio|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Accuray, Inc.|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU (actuatetherapeutics.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HURA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara (TARA)|FATE - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience WHWK|TCRX - Enterprise Value to EBITDA Ratio|Champions Oncology Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio XBiotech Inc. XBIT|CVM: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio OS Therapies, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics|Artiva (ARTV) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio ANL (Adlai Nortye Ltd.)|VERU (Veru Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TPST (Tempest Tx)|Total Company Value to Operating Income Before Depreciation Ratio Xilio Therapeutics Inc (XLO)|RENB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MURA (Mural Oncology plc) - Enterprise Value to Operating Income Before Depreciation|KAPA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio OnKure Therapeutics|Enterprise Value to EBITDA Ratio GDTC|Curis Corp (CRIS) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THAR|EV/EBITDA Multiple advanbiomed.com (ADVB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genprex GNPX|CLDI (Calidi Biotherapeutics Inc.) - Company Value to Operating Income Before Depreciation Ratio|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio purple-biotech.com|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeiGene Ltd. (BGNE)|EV/EBITDA Multiple CKPT|EV/EBITDA Multiple Elevation Oncology Inc. (ELEV)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR: EV/EBITDA Multiple|Company Value to EBITDA NAYA Biosciences Corp (NAYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
